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Abstract This study examined the utilisation patterns of inhaled corticosteroids in England/Wales and the Nether-
lands.Computerised medical records from the GPRD (U.K.) and PHARMO (the Netherlands) databases were used. It
included 284733 English/Welsh and 27 761Dutch adult patientswhowere prescribed inhaled corticosteroids during the
10-year studyperiod.Ourresults showedthat, inbothstudypopulations, overalluseof inhaledcorticosteroidsincreased
over the period studied, with its prevalence rising steeply with age and declining in extreme old age.Decreased use of
bronchodilators and oral corticosteroids in the early treatmentof asthmawas noted in our findings. In addition, a trend
towards the decreasing use of oral corticosteroids concomitant with inhaled corticosteroid therapy was also observed
for both groups.Our study found that only 42.1% of the GPRD and 31.1% of the PHARMO patients received a repeat
prescriptionwithin the expected duration of the preceding inhaled corticosteroid prescription. In conclusion, our study
found many similarities in the prescribing and use of inhaled corticosteroids between the two study populations.The
observation of irregular use of inhaled corticosteroid among a substantial number of patients highlights a need for
further studyinto the reasons for irregular use and its consequences onthe effectiveness oftreatment.
r 2002 Publishedby Elsevier Science Ltd.
doi:10.1053/rmed.2002.1453, available online athttp://www.sciencedirect.com
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Inhaled corticosteroids are themost potent anti-in£am-
matory agents for treating asthma and act in a relatively
non-speci¢c manner by inhibiting a variety of in£amma-
tory cells, cytokine expression, and transcription factors
(1). Their use, initially restricted to patients with severe
asthma, has recently been extended to include patients
with less severe asthma after randomised clinical trials
demonstrated the e⁄cacy of inhaled corticosteroids in
patientswithmilder forms of asthma (2). It has nowbeenReceived 8 april 2002, accepted in revised form 4 September 2002
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Department of Pharmacoepidemiology and Pharmacotherapy,Utrecht
University, POBox 80082,Utrecht,The Netherlands.Fax: +31 (0)30
253 9166; E-mail: h.g.m.leufkens@pharm.uu.nlproposed that inhaled corticosteroids should be consid-
ered as ¢rst-line drugs in asthma prophylaxis for all but
the mildest cases. Current U.K. guidelines outlined by
the British Thoracic Society advise starting treatment
with occasional use of b-agonists. If the asthma remains
poorly controlled and there is an increased requirement
forb-agonistsmore thanonce daily, thenregulardailyuse
of inhaled corticosteroids is recommended (3).The role
of inhaled corticosteroids is that ofmaintenance therapy
to prevent asthma exacerbations (1). For acute, severe,
or rapidly deteriorating, asthma, a short course of an
oral corticosteroid is indicated, combined with the daily
use of inhaled corticosteroids (3).
The objective of this study was to investigate utilisa-
tion patterns and extent of regular use of inhaled corti-
costeroids, as well as their impact on oral corticosteroid
USEOFCORTICOSTEROIDS 579use, in two largepatient samples, one in theU.K. and the
other from the Netherlands. Information was obtained
from the General Practice Research Database (GPRD)
that contains the computerised medical records of a
large group of medical practices in England and Wales
(4), and from the PHARMO database that links commu-
nity pharmacy and hospital data from several regions of
the Netherlands (5). Both databases have been widely
used in epidemiological drug research (6^10).
METHODS
Databases
EnglandandWales
The data for England andWales were obtained from the
GPRD, owned by the Department of Health and mana-
ged by the Medicines Control Agency in the U. K. (4).
This database comprises the entire computerised medi-
cal records of a sample of general practitioners (GPs) in
the country.GPs play a key role in the U. K. health-care
system, as they are responsible for primary health care
and specialist referrals. All members of the population
are registered with a single practice, which centralises
the medical information not only from the GPs but also
from specialist referrals and hospital attendances. The
current study included 683 practices currently incorpo-
rated in the GPRD and thereby comprised a 6% sample
of the U. K. population.Clinical data are stored and re-
trievedbymeans ofOxfordMedical Information Systems
(OXMIS) and READ codes for diseases that are cross-re-
ferenced to the International Classi¢cation of Diseases
(ICD-9). The prescription information is cross-refer-
enced to the British National Formulary (11). A compar-
ison of GPRD with the Fourth Morbidity Survey in
General Practice found that GPRD was a valid source of
epidemiological information on respiratory disease (12).
The Netherlands
The PHARMOdatabase contains the drugdispensing re-
cords fromcommunitypharmacies and the admission re-
cords from hospitals in a population of about 500 000
patients in the Netherlands (about 3% of the total popu-
lation). The PHARMO database is con¢ned to the com-
plete population of 18 medium-sized cities in the
Netherlands and collects prescriptions and hospital ad-
mission records of residents. The drug dispensing and
hospital admission histories are linked on an individual
basis using probability methods (5). The database con-
tains information on the use of prescription medication,
hospital discharge diagnoses (ICD-9), and operations or
procedures that were performed in the hospital. The
prescription information is cross-referenced to the ATC
classi¢cation (13).Study population andmethods
The two study cohorts consisted of all adult patients (18
years or older) who received one or more prescriptions
for inhaled corticosteroids during the period of time of
study data collection ( January 1987^December 1997 for
GPRD and January1987^December1998 for PHARMO).
The cohortentrydate for each inhaledcorticosteroid ta-
ker was de¢ned as the date of the ¢rst inhaled corticos-
teroid prescription after enrolment in PHARMO or
GPRD. Patients were censored at the time of death, end
of study period, or, for GPRD, patient’s change of prac-
tice.Dividing the total duration of inhaled corticosteroid
use by the total observation time of GPRDmade a point
prevalence estimate for inhaled corticosteroid use.
The total observation time was the cumulative number
of patients registered in the database at 1 July of each
calendar year. The duration of each prescription was
based on the median recorded duration of use (28 days
in GPRD and 40 days in PHARMO).This prevalence esti-
mate provided a cross-sectionalmeasure of inhaled cor-
ticosteroid utilisation. The prevalence of inhaled
corticosteroid use could not be estimated for PHARMO
prior to1991, as no denominator data were available.No
prevalence estimatesweremade forGPRD prior to1990
because of the small number of practices included at that
time and for 1997 because data collection was stopped
that year.
The use of oral corticosteroids in the year before and
after start of inhaled corticosteroid therapy was mea-
sured. An analysiswas done over calendar time (covering
a 1-year period of therapy) and included only patients
who started inhaled corticosteroid therapy at least 1-
year after start of data collection. Kaplan^Meier survi-
val analysis was conducted in order to estimate the pro-
portion of people who received oral corticosteroids
within the ¢rst year of inhaled corticosteroid treatment.
Patients were followed from the ¢rst inhaled corticos-
teroidprescriptionuntil 3months after the lastprescrip-
tion, or until date of censoring (whichever came ¢rst).
Theproportion of peoplewho received an oral corticos-
teroid prescription in the year preceding the start of in-
haledcorticosteroid treatmentwas also estimated.Prior
use of bronchodilators was also evaluated.
The regularity of inhaled corticosteroid treatment
and the time between two consecutive prescriptions
was examined. For each patient, we randomly selected
an inhaled corticosteroid prescription. For the patients
with use prior to this selected prescription, the percen-
tage of patients who received a prescription in the 6
months before the selected inhaled corticosteroid pre-
scription was estimated. Furthermore, it was deter-
mined whether the selected inhaled corticosteroid
prescription was given within the expected duration of
the previous prescription (based on the cumulative num-
ber of doses divided by the prescribed daily dose).
580 RESPIRATORYMEDICINEPatients starting PHARMO/GPRD data collection in the
previous 6 months were excluded from the analysis.
For the GPRD population, the indication for inhaled
corticosteroid treatment was obtained by reviewing
the morbidity recorded at the date on which a new
course of treatment was started. At the commence-
mentof newdrug treatment, theGPs are required to re-
cord the indication for treatmenton the same date in the
medical record. This analysis included patients who re-
ceived their ¢rst inhaled corticosteroid prescription at
least1-year after start of data collection for thatpatient.
RESULTS
There were 284 733 inhaled corticosteroid users identi-
¢edinGPRD and 27 761in PHARMO(Table1).Themajor-
ity of users in both populations were women (55.3% in
GPRD and 53.9% in PHARMO). The age distribution of
inhaled corticosteroid users was comparable with med-
ian age of 48 years in GPRD and 49 years in PHARMO.
There were substantive di¡erences in the application
form of the inhaled corticosteroid. In England andWales,
inhaled corticosteroids were administered mostly by a
pressurised metered dose inhaled (pMDI) (73.2% of all
prescriptions) while in the Netherlands, dry powder ad-TABLE 1. Characteristics of inhaled corticosteroidusers
Totalnumberof users
Numberof women
Age (year)
Mean
Median
Follow-up per person (year)
Mean
Medium
Totalnumberof inhaledprescriptions
Application form
pMDI
Drypowder
Nebuliser
Type of inhaled corticosteroids
Beclomethasone dipropionate
Budesonide
Fluticasone propionate
Dailydose (mg beclomethasone equivalent)a
1^400
401^800
801^1500
1500+
aDailydosewasmissing in 6.0% ofthe PHARMOand18.4% oftministrationwas considerablymorepopular (83.0% of all
prescriptions). The distribution of prescribed daily dose
was comparable between the populations: 44.6% of the
GPRD patients were prescribed a daily dose of 400mg
beclomethasone equivalent or less compared to 46.8%
of the PHARMOpatients.
Figure 1 shows the use of inhaled corticosteroids in
England/Wales and the Netherlands. It was found that
the prevalence of use rises steeply with age in both po-
pulations, with a tendency towards lower use in extreme
old age. In GPRD, women used inhaled corticosteroids
more frequently thanmenup to the age of 70 years,with
more frequent use among men after this age. A similar
pattern was seen in PHARMO, with the reversal in the
sex ratio of use taking place at 60 years of age. Use of
inhaled corticosteroids was greater in England/Wales
compared with the Netherlands: 1.4% in GPRD and 1.1%
in PHARMO. Use of inhaled corticosteroids increased
signi¢cantly over calendar time (Table 2). In GPRD, 1.1%
of adult population used inhaled corticosteroids in 1991
compared to 1.7% in 1996. For PHARMO, these ¢gures
were 0.8 and1.4%, respectively.
In the analysis of the prescribing patterns and regular-
ity of use, it was found that 80.5% of the GPRD patients
and 76.6% of the PHARMO patients with prior use had
received a prescription for inhaled corticosteroids inGPRD PHARMO
284733 27 761
157561 (55.3%) 14955 (53.9%)
48.5 49.6
48 49
2.8 4.2
2.4 3.6
3322 210 257578
73.2% 16.3%
25.8% 83.0%
1.0% 0.6%
81.4% 63.6%
13.8% 23.4%
4.7% 13.0%
44.6% 46.8%
27.4% 36.0%
16.0% 11.3%
12.0% 5.9%
he GPRD prescriptions.
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FIG. 1. Prevalence of use of inhaled corticosteroid strati¢ed by age and sex.
USEOFCORTICOSTEROIDS 581the 6 months before the selected prescription (Table 2).
Taking into account the expected duration of inhaled
corticosteroid treatment, 42.1% of the GPRD and 31.1%
of the PHARMO patients received this repeat prescrip-
tion within the expected duration of the preceding in-
haled corticosteroid prescription. Elderly patients were
more likely to receive repeat prescriptions within the
period of duration of use: 50.7% of the GPRD patients
and 41.2% of the PHARMOpatients aged 75 years or old-
er, compared to 34.0%of theGPRDpatients and 24.7% of
the PHARMOpatients younger to 45 years.Table 3 follows the changes in the use of inhaled corti-
costeroid treatment over the calendar time1987^1997. It
shows that the proportion of women and age of patients
starting treatmentdid not vary substantively over calen-
dar time. In 1990, the average age of the user was 50
years in GPRD and 56.2% werewomen, compared to an
average age of 50 years and 57.9% women in 1996. In
PHARMO, the average ageswere 50 and 49 and the pro-
portion of women 54.6 and 55.5%, respectively. There
was a decrease over calendar time in the proportion of
patients who started inhaled corticosteroid treatment
TABLE 2. Regularityof inhaled corticosteroid treatment
GPRD PHARMO
Rxinprevious 6
monthsa (%)
Repeat Rxwithin
treatmentperioda (%)
Rxinprevious 6
monthsa (%)
Repeat Rxwithin
treatmentperioda (%)
Overall 80.5 42.1 76.6 31.1
Sex
Women 79.7 41.0 74.5 29.7
Men 81.4 43.5 78.9 32.6
Age (year)
18^44 70.8 34.0 68.4 24.7
45^59 81.5 42.1 75.3 29.3
60^74 88.8 49.3 82.0 35.0
75+ 89.6 50.7 87.6 41.2
aFor patientswho previouslyreceived another inhaled corticosteroidprescription.
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USEOFCORTICOSTEROIDS 583after ¢rst using bronchodilators. This proportion de-
creased by12% from1990 to1996 in both populations.
There was a trend over calendar time towards oral
corticosteroids being used less frequently during inhaled
corticosteroid therapy (Fig. 2). In 1990, 25.0% of the in-
haled corticosteroid users in GPRD were prescribed an
oral corticosteroid during the ¢rst year of inhaled corti-
costeroid therapy as compared to19.5% in1996. InPHAR-
MO, this percentage of concomitant use of oral
corticosteroids decreased from 19.9% in 1990 to 15.1% in
1996.Oral corticosteroids were also used less frequently
over time in the year preceding the start of the inhaled
corticosteroid therapy.
Of the GPRD patients who started inhaled corticos-
teroid treatment at least1year after start of data collec-
tion, asthma was the most frequently reported
indication for treatment. Less frequent indications in-
cluded bronchitis and other obstructive pulmonary dis-
ease. In the patients aged less than 45 years, 96.6% of
the recorded respiratory morbidity concerned asthma
and 3.4% bronchitis or other obstructive pulmonary dis-
ease. For patients aged 75 years or older, these ¢gures
were 49.9 and 50.1%, respectively.No information on the
indication for treatment was available for the PHARMO
patients.
DISCUSSION
This study examined the utilisation patterns of inhaled
corticosteroids of two large populations in two coun-
tries.The elderly in particular were found to use inhaled
corticosteroids frequently. In both study populations,
England/Wales and the Netherlands, inhaled corticos-
teroid use has increased substantially over time. Inhaled
corticosteroid treatment was initiated more frequently
over calendar timewithout prior use of bronchodilators
and its concomitant use with oral corticosteroids
showed a decline over calendar time inbothpopulations.
The results also show that, in both populations, a sub-
stantial proportion of patients were not using inhaled
corticosteroids continuously. Our ¢ndings suggest that
younger patients, in particular, were more likely to use
inhaled corticosteroids for symptomatic treatment than
regular treatment.The maximum bene¢cial e¡ect of in-
haled corticosteroids may take from 1 to 3 months to
achieve (14). Thus, a possible reason for irregular use by
patients may be that this slow onset of the drug’s e¡ec-
tiveness does not convince patients that inhaled corti-
costeroids are contributing to the asthma control. A
study evaluating compliance to asthma drugs found that
it was signi¢cantly lower in patients using inhaled corti-
costeroids compared to those using theophylline. The
di¡erencewas partly attributed to the perception of im-
mediate bene¢cial e¡ects of theophylline (15).This expla-
nation is supported by the ¢ndings of a case^ control
584 RESPIRATORYMEDICINEstudy of patients hospitalised for an asthma exacerba-
tion. It found that cases expressed less interest in opti-
mal usage of inhaled corticosteroids and more
con¢dence in bronchodilators (16).Our results are in line
with a cross-sectional reviewof asthma treatment in ¢ve
general practices in England. Among the patients using
inhaled corticosteroids, only 35% received this treat-
ment regularly (17).
There are data to suggest that regular use of inhaled
corticosteroids provides a better overall control of asth-
ma compared to symptomatic use. In epidemiological
studies, regular use of inhaled corticosteroids was asso-
ciatedwith a decreasedriskof death from asthma (18,19).
It was also reported that sporadic use of inhaled corti-
costeroids couldbe associatedwith higher rates ofdeath
from asthma (18).Use of inhaled corticosteroids in acute
asthma exacerbations may also be less e¡ective. A ran-
domised double-blind study in children with a severe
asthma exacerbation found that the degree of improve-
ment in pulmonary function in the initial 4 h among
those treated with an oral corticosteroid was about
twice that in those given an inhaled corticosteroid. A
possible reason for this ¢ndingmay be suboptimal deliv-
ery of inhaled corticosteroids into the lung in case of se-
vere airway narrowing (20). Further research is needed
to assess the e¡ectiveness of irregular use of inhaled cor-
ticosteroids.
The increase in the use of inhaled corticosteroids
shown in this study is consistent with previously re-
ported ¢ndings (21).Over a 7-year period, inhaled corti-
costeroid use almost doubled in both England/Wales and
the Netherlands.One possible explanationmay be an in-
creasedprevalence of asthma.Therehavebeen anumber
of epidemiological studies repeated in more or less the
same population with the same or similar methods,
which found that the asthma prevalence and severity
have increased (22). The increased utilisation may also
be explained, partly, by changing prescription practices
in the treatment of asthma. In both England/Wales and
the Netherlands, prior use of bronchodilators has de-
creased over time. At the end of the study, almost half
of the patients started inhaled corticosteroid treatment
without recent prior use of bronchodilators. Similarly,
use of oral corticosteroids also decreased, along with
its use prior to, and during, inhaled corticosteroid treat-
ment.
A surprising ¢nding in this study was that in both po-
pulations a substantive proportion of patients was not
treated with bronchodilators prior to starting inhaled
corticosteroids. One possible explanation for this may
be that asthma treatment (i.e., bronchodilators) was
started in the hospital and not recorded in our data-
bases. However, we measured use of bronchodilators
over a period of 1 year and any long-term treatment is
likely to be recorded in our databases. In the U.K. treat-
ment that is started in thehospital is generally continuedby the GP. Another possible explanation for this ¢nding
is the variation in the treatment patterns in general clin-
ical practice. A recent study in six general practices in
England found that 58% of the asthma patients used
treatment regimens that were not consistent with treat-
ment guidelines.The reasons for this inappropriatemed-
ication use resulted mostly of underuse of inhaled
corticosteroids in the setting of regular bronchodilator
use (23). Further research is needed to better under-
stand the reasons for underuse of bronchodilators in pa-
tients using inhaled corticosteroids.
Information for this study was derived from prescrip-
tion information. This approach has limitations: the ac-
tual amounts of drugs taken by patients could not be
assessed. Patients may not have taken the drug or have
taken it at di¡erent dose and duration than that pre-
scribed by the physician. Nevertheless, large gaps be-
tween re¢ll prescriptions may suggest some problems
with compliance and regularity of use. In GPRD, the GP
dose instructions were not collected systematically. It
was recorded because the text had to be coded by the
researchers. In both populations, possible instructions
of dosereductions in case of better asthma control were
not recorded.
In conclusion, inhaled corticosteroids are frequently
being used in England/Wales and the Netherlands, and
their usage has almost doubled over the period covered
by our study.Our results indicate irregular use of inhaled
corticosteroid among a substantial number of patients,
highlighting a need for further studies to elucidate the
reasons for irregular use and the e¡ectiveness of inhaled
corticosteroids with irregular use.
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